Dr. Vernon Sutton, MD
Pediatrics (Pediatrics Physician)
At a glance
- Medical school
- University of Kentucky College of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
Licensed in Texas since 1999, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: University of Kentucky College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
TX license K8506 (first issued 1999; active) -
Clinical Genetics (M.D.) Physician
TX license K8506 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Texas Childrens Physician Group (671 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 4 companies reported 15 payments worth $26,423 in total to this clinician.
| BioMarin Pharmaceutical Inc. | $16,250 |
|---|---|
| Amicus Therapeutics, Inc. | $4,527 |
| Immedica Pharma US, Inc. | $4,000 |
| Zevra Therapeutics Inc | $1,647 |
| Travel and Lodging | $10,664 |
|---|---|
| Consulting Fee | $7,612 |
| Compensation for services other than consulting (speaking, faculty) | $5,850 |
| Honoraria | $1,647 |
| Education | $543 |
| Food and Beverage | $108 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| BioMarin Pharmaceutical Inc. May 21, 2025 | Travel and Lodging travel to Kyoto, Japan · in-kind | $9,011 |
| BioMarin Pharmaceutical Inc. Sep 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,850 |
| Amicus Therapeutics, Inc. Apr 22, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $3,612 |
| Immedica Pharma US, Inc. Dec 5, 2025 | Consulting Fee | $2,000 |
| Immedica Pharma US, Inc. Dec 5, 2025 | Consulting Fee | $2,000 |
| Zevra Therapeutics Inc May 26, 2025 | Honoraria Olpruva · Urea Cycle Disorders (UCDs) | $1,647 |
| Amicus Therapeutics, Inc. Apr 22, 2025 | Travel and Lodging POMBILITI; OPFOLDA · POMPE DISEASE · travel to Los Angeles, CA | $915 |
| BioMarin Pharmaceutical Inc. Aug 31, 2025 | Education in-kind | $543 |
| BioMarin Pharmaceutical Inc. Sep 24, 2025 | Travel and Lodging travel to Kyoto, Japan · in-kind | $510 |
| BioMarin Pharmaceutical Inc. Sep 24, 2025 | Travel and Lodging travel to Kyoto, Japan · in-kind | $127 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Immedica Pharma US, Inc. Dec 5, 2025 | Consulting Fee | $2,000 |
| Immedica Pharma US, Inc. Dec 5, 2025 | Consulting Fee | $2,000 |
| BioMarin Pharmaceutical Inc. Sep 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,850 |
| BioMarin Pharmaceutical Inc. Sep 24, 2025 | Travel and Lodging travel to Kyoto, Japan · in-kind | $510 |
| BioMarin Pharmaceutical Inc. Sep 24, 2025 | Travel and Lodging travel to Kyoto, Japan · in-kind | $127 |
| BioMarin Pharmaceutical Inc. Sep 24, 2025 | Travel and Lodging travel to Kyoto, Japan · in-kind | $54.95 |
| BioMarin Pharmaceutical Inc. Sep 24, 2025 | Travel and Lodging travel to Kyoto, Japan · in-kind | $45.96 |
| BioMarin Pharmaceutical Inc. Aug 31, 2025 | Education in-kind | $543 |
| Zevra Therapeutics Inc May 26, 2025 | Honoraria Olpruva · Urea Cycle Disorders (UCDs) | $1,647 |
| BioMarin Pharmaceutical Inc. May 21, 2025 | Travel and Lodging travel to Kyoto, Japan · in-kind | $9,011 |
| Amicus Therapeutics, Inc. Apr 22, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $3,612 |
| Amicus Therapeutics, Inc. Apr 22, 2025 | Travel and Lodging POMBILITI; OPFOLDA · POMPE DISEASE · travel to Los Angeles, CA | $915 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $424,843 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Ultragenyx Pharmaceutical Inc. - Study name not reported
Ultragenyx Pharmaceutical Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.